Novartis | NOVN - Interest Expense On Debt

Stock Price
113.70
Daily Change
-2.58 -2.22%
Monthly
-4.95%
Yearly
22.87%
Q2 Forecast
111.47

Novartis reported $304M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Alcon AG USD 54M 3M Dec/2025
Amgen USD 653M 32M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Autolus Therapeutics Ltd USD 10.52M 17.35M Sep/2025
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Fresenius EUR 81M 5M Sep/2025
Fresenius Medical Care EUR 85M 8.1M Dec/2025
Galapagos EUR 1.72M 940K Sep/2025
Genmab DKK 10M 27M Dec/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
J&J USD 43M 25M Mar/2026
Lonza CHF 84M 14M Jun/2025
Merck EUR 121M 5M Dec/2025
Merck USD 412M 85M Dec/2025
Novartis USD 304M 23M Dec/2025
Novartis USD 281M 8M Sep/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Orion EUR 1.4M 800K Mar/2026
Pfizer USD 711M 59M Dec/2025
Philips EUR 109M 31M Dec/2025
Recordati EUR 22.13M 1.43M Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 178M 203M Mar/2026
UCB EUR 49M 29M Dec/2025